Immunogenicity and Efficacy of TNX-1800, A Live Virus Recombinant Poxvirus Vaccine Candidate, Against SARS-CoV-2 Challenge in Nonhuman Primates
M. Awasthi, A. Macaluso, D. Myscofski, J. Prigge, F. Koide, R. S. Noyce, S. Fogarty, H. Stillwell, S. J. Goebel, B. Daugherty, F. Nasar, S. Bavari, S. Lederman
This study evaluates the immunogenicity and efficacy of TNX-1800, a poxvirus vaccine expressing SARS-CoV-2 spike protein, in nonhuman primates challenged with SARS-CoV-2.
bioRxiv · Sep 19, 2023Immunology